(Q37416806)

20 August 2017

1 reference

title

Tumoral angiogenesis and breast cancer (English)

1 reference

20 August 2017

1 reference

P Khosravi Shahi

1

1 reference

20 August 2017

A Soria Lovelle

series ordinal

2

1 reference

20 August 2017

G Pérez Manga

series ordinal

3

1 reference

20 August 2017

publication date

1 March 2009

1 reference

Clinical and Translational Oncology

20 August 2017

published in

1 reference

20 August 2017

volume

11

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

138-142

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-009-0329-7

20 August 2017

exact match

0 references

cites work

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-009-0329-7

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

12 December 2020

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

12 December 2020

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

12 December 2020

[A new therapeutic strategy in breast cancer: metronomic chemotherapy]

1 reference

12 December 2020

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

12 December 2020

Tumoral angiogenesis: review of the literature

1 reference

12 December 2020

Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer

1 reference

12 December 2020

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

12 December 2020

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

12 December 2020

Mechanisms of angiogenesis

1 reference

12 December 2020

Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment

1 reference

12 December 2020

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

1 reference

12 December 2020

The biology of VEGF and its receptors

1 reference

12 December 2020

Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family

1 reference

12 December 2020

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Metronomic chemotherapy: an antiangiogenic scheduling

1 reference

12 December 2020

CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha

1 reference

12 December 2020

1 reference

12 December 2020

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

1 reference

12 December 2020

Hypoxia--a key regulatory factor in tumour growth

1 reference

12 December 2020

Regulation of angiogenesis via vascular endothelial growth factor receptors.

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Metronomic scheduling: the future of chemotherapy?

1 reference

12 December 2020

[Angiogenesis and neoplasias]

1 reference

12 December 2020

Regulation of distinct steps of angiogenesis by different angiogenic molecules

1 reference

12 December 2020

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

12 December 2020

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

12 December 2020

Regulation of angiogenesis by hypoxia: role of the HIF system

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

10.1007/S12094-009-0329-7

Identifiers

DOI

1 reference

20 August 2017

1 reference